Citigroup
TGTX icon

Citigroup’s TG Therapeutics TGTX Stock Holding History

Citigroup’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$824K Sell
15,000
-15,000
-50% -$614K ﹤0.01% 3588
2026
Q1 		$997K Buy
+30,000
New +$894K ﹤0.01% 3118
2024
Q3 		– Sell
-74,900
Closed -$1.33M – 5800
2024
Q2 		$1.33M Buy
74,900
+35,000
+88% +$558K ﹤0.01% 2682
2024
Q1 		$607K Sell
39,900
-5,000
-11% -$79.7K ﹤0.01% 3434
2023
Q4 		$767K Sell
44,900
-5,000
-10% -$58.1K ﹤0.01% 3066
2023
Q3 		$417K Sell
49,900
-3,500
-7% -$48.8K ﹤0.01% 3195
2023
Q2 		$1.33M Buy
+53,400
New +$1.38M ﹤0.01% 2598
2023
Q1 		– Sell
-130,000
Closed -$1.54M – 5853
2022
Q4 		$1.54M Sell
130,000
-536,800
-81% -$3.9M ﹤0.01% 2248
2022
Q3 		$3.95M Buy
666,800
+166,800
+33% +$1.09M ﹤0.01% 1683
2022
Q2 		$2.13M Buy
+500,000
New +$3.12M ﹤0.01% 2057
2022
Q1 		– Sell
-125,000
Closed -$2.38M – 6598
2021
Q4 		$2.38M Buy
+125,000
New +$3.25M ﹤0.01% 2475
2021
Q1 		– Sell
-60,200
Closed -$3.13M – 7339
2020
Q4 		$3.13M Hold
60,200
– – ﹤0.01% 2436
2020
Q3 		$1.61M Hold
60,200
– – ﹤0.01% 2848
2020
Q2 		$1.17M Sell
60,200
-11,700
-16% -$188K ﹤0.01% 3383
2020
Q1 		$707K Sell
71,900
-18,300
-20% -$231K ﹤0.01% 3534
2019
Q4 		$1M Buy
90,200
+7,100
+9% +$54K ﹤0.01% 3751
2019
Q3 		$467K Buy
83,100
+30,900
+59% +$215K ﹤0.01% 4407
2019
Q2 		$452K Buy
52,200
+36,600
+235% +$277K ﹤0.01% 4521
2019
Q1 		$125K Sell
15,600
-15,200
-49% -$82.2K ﹤0.01% 5542
2018
Q4 		$126K Buy
30,800
+11,600
+60% +$57.6K ﹤0.01% 5458
2018
Q3 		$108K Buy
+19,200
New +$219K ﹤0.01% 5826

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Citigroup's TGTX Position: Q2 2026 in Review

Citigroup increased its TG Therapeutics (TGTX) stake by 9.6% in Q2 2026, buying an estimated $1.4M and bringing the position to 388,087 shares worth $21.3M. The position accounts for 0.01% of the portfolio, ranked #1135.

Citigroup first reported a position in TGTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $27M in Q3 2025. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Citigroup held 388,087 shares of TG Therapeutics worth $21.3M as of Q2 2026.
  • Citigroup bought 34,108 TG Therapeutics shares in Q2 2026, an estimated $1.4M.
  • TG Therapeutics made up 0.01% of Citigroup's portfolio in Q2 2026, its #1135 holding.
  • Citigroup first reported a position in TG Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's TG Therapeutics position peaked at $27M in Q3 2025.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.